Longer durationof action. Newer analogues glargine and detemir (Fig. 36.2) have become widely used, especially in type 1 diabetes. Small changes in the amino acid structure of glargine result in a significant slowing of absorption from subcutaneous depots. In contrast, detemir owes its protracted ...
Molecular Design and Pharmacological Properties of GZR4 GZR4 is an ultra-long-acting, once-weekly insulin analog developed through innovative molecular design. Three amino acid substitutions were made to the main chain of human insulin (A14E, B16H, B25H), the B30 threonine of the insulin B-ch...
However, known long-acting insulin analogues with a structure similar to that of the compounds included in this application, constituting progress in diabetes treatment, exhibit several undesirable features, e.g. the insulin analogue widely used in therapy—insulin glargine—in spite of a microdeposit...
Due to these pharmacological properties, it has been suggested that this type of insulin may have a role in facilitating the transition from continuous intravenous insulin infusion to subcutaneous maintenance therapy in patients with DKA. In one trial the authors hypothesized that the initiation of a...
Iconography : Pharmacological variability of insulins degludec and glargine 300 U/mL: Equivalent or not?L MonnierC Colette
be selected in future, being able to reduce nocturnal basal insulin infusion for a limited period of time offers a means to reduce nocturnal hypoglycaemia without the need for additional pharmacological therapy. In those treated with CSII this represents a successful solution to the problem of noctu...
pylori-related carcinogenesis may provide novel pharmacological targets for microorganism-related cancers. Hepatitis C virus has also been reported to cause permanent liver damage and hepatocellular carcinoma (Amitrano et al. 1990, Farinati et al. 1992), at least in part through oxidative stress, ...
Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled Type 2 diabetes in the United Kingdom p pObjective/p pExenatide belongs to a new therapeutic class in the treatment of diabetes (incretin mimetics), allowing glucose-dependent glycaemic...
Samples from the primary stability studies of Suliqua (a lixisenatide/insulin glargine combination), the insulin lispro Sanofi drug product (DP), and the insulin lispro Sanofi drug substance (DS) were analyzed with the in vitro insulin cell-based bioassay and in vivo rabbit blood sugar test. ...
The key element is also the discriminant analysis which allows determining which biochemical or anthropometric variables discriminate the patients best before and after treatment which, at the same time, is the confirmation of the pharmacological therapy efficacy. Moreover, the relationship between the ...